Editas Medicine, Inc.

EDIT Healthcare Biotechnology

Editas Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 25.4% from fiscal 2024. In the quarter to June 2026, revenue grew 232.3%, EPS grew 76.2% and free cash flow grew 40.7%, each against the same quarter a year earlier.

2.47 0.28 −10.18%
Market cap
$422.3M
P/E
0.0×
Fwd P/E
−2.7×
Dividend yield
—
F-score
2/9
Altman Z
−13.39
Beneish M
−2.46
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Total current assets
176.89 163.90 128.07 218.07
Total non-current assets
24.86 22.64 21.27 19.30
Total Assets
201.75 186.53 149.34 237.36
Total current liabilities
61.77 46.25 39.78 68.43
Total non-current liabilities
126.53 113.00 105.15 63.65
Total liabilities
188.30 159.25 144.93 132.08
Common Equity (Total)
13.45 27.29 4.41 105.28
Shareholders Equity (Total)
13.45 27.29 4.41 105.28

Show all line items

In millions of $ except per-share values · columns are period end dates